Skip to main content

Advertisement

Table 2 Disease activity indices and disease-specific autoantibodies in patients with rheumatic diseases

From: Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study

Systemic sclerosis n = 120
 HAQ-DI, mean (SD) 0.99 (0.85)
 SHAQ score, mean (SD) 0.87 (0.68)
  Digestive VAS, mean (SD) 0.54 (0.79)
  Pulmonary VAS, mean (SD) 0.63 (1.09)
  Raynaud’s VAS, mean (SD) 0.78 (0.78)
  Digital ulcer VAS, mean (SD) 0.41 (0.71)
  Overall disease severity VAS, mean (SD) 1.05 (0.88)
 ANA, n (%) 105 (87.5)
 Anti-topoisomerase I antibody, n (%) 49 (40.8)
 Anti-centromere antibody, n (%) 23 (19.2)
Rheumatoid arthritis n = 120
 DAS28 (ESR), mean (SD) 3.56 (0.12)
 Patient global health, mean (SD) 35.21 (2.17)
 Rheumatoid factor, n (%) 109 (90.8)
 Anti-citrullinated protein antibody, n (%) 76 (63.3)
Systemic lupus erythematosus n = 120
 SLEDAI-2K, mean (SD) 6.26 (1.22)
 ANA, n (%) 116 (96.7)
 Anti-Smith antibody, n (%) 47 (39.2)
 Anti-ds DNA antibody, n (%) 90 (75.0)
 C3, mg/dL, mean (SD) 74.22 (4.15)
 C4, mg/dL, mean (SD) 12.78 (1.15)
Sjogren’s syndrome n = 120
 ESSDAI, mean (SD) 1.52 (0.22)
 ANA, n (%) 110 (91.7)
 Anti-SSA/Ro autoantibody, n (%) 69 (57.5)
 Anti-SSB/La autoantibody, n (%) 81 (67.5)
  1. HAQ-DI, Health Assessment Questionnaire Disability Index; SHAQ, Scleroderma-Specific Health Assessment Questionnaire; ANA, antinuclear antibodies; DAS28-ESR, disease activity score evaluated with erythrocyte sedimentation rate; SLEDAI-2K, systemic lupus erythematosus disease activity index 2000; ESSDAI, EULAR Sjogren’s syndrome disease activity index